3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
24
Neoplasm Metastasis
8
Leukemia, Myeloid, Acute
8
Carcinoma, Renal Cell
7
Ovarian Neoplasms
6
Lymphoma, Non-Hodgkin
6
Carcinoma, Non-Small-Cell Lung
6
Stomach Neoplasms
5
Colorectal Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Neuroblastoma
4
Neoplasms
4
Lymphoma
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Esophageal Neoplasms
3
Colonic Neoplasms
3
Uveal Melanoma
2
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Rectal Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Mesothelioma, Malignant
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Interventions
Sorafenib
26
Nivolumab
21
pembrolizumab
15
Bevacizumab
14
lenvatinib
12
atezolizumab
9
Cyclophosphamide
9
Ipilimumab
8
durvalumab
6
camrelizumab
5
apatinib
5
Specimen Handling
5
Radiosurgery
5
tislelizumab
4
fludarabine
4
Immunotherapy, Adoptive
4
Fluorouracil
4
Doxorubicin
4
tremelimumab
3
toripalimab
3
sintilimab
3
regorafenib
3
cabozantinib
3
X-Rays
3
Magnetic Resonance Spectroscopy
3
Injections
3
Everolimus
3
Ethiodized Oil
3
Erlotinib Hydrochloride
3
tepotinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Hepatocellular
×
Interleukin-2
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled